drug - International Pharmaceutical Industry

News

XenoGesis and BioAscent forge alliance to offer enhanced integrated drug discovery services

XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal c...

16 May 2018 News alliance | BioAscent

Continue Reading →

News

AZ’ lung cancer drug Tagrisso backed for first-line use

European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting. The Committee for Medicinal Products ...

1 May 2018 News AZ | backed

Continue Reading →

News

Starpharma completes US New Drug Application for VivaGel BV

VivaGel BV stands to be the first and only product approved for the prevention of recurrent BV Australian pharma giant Starpharma today announced that its rollin...

1 May 2018 News application | BV

Continue Reading →

News

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening r...

20 April 2018 News Abeona | designation

Continue Reading →

News

BioAscent establishes integrated drug discovery services offering

Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences Dr Phil Jones BioAscent Discove...

13 April 2018 News BioAscent | discovery

Continue Reading →

News

Dongkoo Bio signs deal to sell OTC prostate drug

Cernilton treats benign prostatic hyperplasia (BPH) and chronic prostatitis. South Korea based Dongkoo Bio & Pharma has signed a licensing-in deal with ...

3 April 2018 News Cernelle | Dongkoo

Continue Reading →

News

Teva, Valeant price-hike plans trigger warnings under California's new transparency law: report

California is among a group of states that have taken drug prices into their own hands, with lawmakers last year passing a bill aimed at shining new light on the...

3 April 2018 News california | drug

Continue Reading →

News

£2m backing from Archangels and SIB for UK drug delivery company BDD

Funding will enable BDD to scale up GMP manufacture of revolutionary time controlled “pill within a pill” Archangels, the Edinburgh-based business ange...

20 March 2018 News archangels | BDD

Continue Reading →

News

Avacta Group plc announces positive outcome of proof-of-concept study with Glythera and follow-on drug development partnership

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the develo...

16 January 2018 News antibody | biotherapeutics

Continue Reading →

Volume 9 Issue 4

Accurate Protein Electrostatics Add a New Dimension to Structure-based Drug Design

The combination of advanced molecular force fields and improved visualisation capabilities has enabled chemists to expand their ligand-only view of the electrostatic...

4 January 2018 Volume 9 Issue 4 accurate | design

Continue Reading →

Future-ready ADCs – advanced vial solutions for superior stability and performance

Alternative Drug Delivery Routes: Opportunities, Challenges, and How to Overcome Them

Bridging the gap between R&D and GMP

Current Edition

Current Edition

Subsection - CDMO

Subsection - Injectables

Subsection - Neurodegenerative Diseases

Subsection - Nasal & Pulmonary

XenoGesis and BioAscent forge alliance to offer enhanced integrated drug discovery services

AZ’ lung cancer drug Tagrisso backed for first-line use

Starpharma completes US New Drug Application for VivaGel BV

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

BioAscent establishes integrated drug discovery services offering

Dongkoo Bio signs deal to sell OTC prostate drug

Teva, Valeant price-hike plans trigger warnings under California's new transparency law: report

£2m backing from Archangels and SIB for UK drug delivery company BDD

Avacta Group plc announces positive outcome of proof-of-concept study with Glythera and follow-on drug development partnership

Accurate Protein Electrostatics Add a New Dimension to Structure-based Drug Design

International Pharmaceutical Industry